search
Back to results

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)

Primary Purpose

Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bevacizumab
Paclitaxel
Carboplatin
specialized pathology review (Germany only)
Sponsored by
AGO Study Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Genital Diseases, Female focused on measuring Ovarian Carcinoma, Bevacizumab, Paclitaxel, Carboplatin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed written informed consent obtained prior to initiation of any study specific procedures and treatment as confirmation of the patients awareness and willingness to comply with the study requirements
  • Primary diagnosis is confirmed by specialized pathology review (Germany only)
  • Females aged ≥ 18 years
  • Histologically confirmed, newly diagnosed

    • Epithelial ovarian carcinoma
    • Fallopian tube carcinoma
    • Primary peritoneal carcinoma AND FIGO stage IIb - IV (all grades and all histological types)
  • Patients should have already undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction according to the GCIG Conference Consensus Statement. There must be no planned surgical debulking prior to disease progression. Patients with stage III and IV disease in whom initial surgical debulking was not appropriate or possible will still be eligible providing

    • the patient has a histological diagnosis and
    • debulking surgery prior to disease progression is not foreseen
  • Patients must be able to commence cytotoxic chemotherapy within 8 weeks of cytoreductive surgery. The first dose of bevacizumab can be omitted in both arms if the investigator decides to start chemotherapy within 4 weeks of surgery.
  • ECOG 0-2
  • Life expectancy > 3 months
  • Adequate bone marrow function (within 14 days prior to randomization)

    • ANC ≥ 1.5 x 10^9/L
    • PLT ≥ 100 x 10^9/L
    • Hb ≥ 9 g/dL (can be post-transfusion)
  • Adequate coagulation parameters (within 14 days prior to randomization)

    • Patients not receiving anticoagulant medication who have an INR ≤ 1.5 and an aPTT ≤ 1.5 x ULN
    • The use of full-dose oral or par-enteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to institution medical standard) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization.
  • Adequate liver function (within 14 days prior to randomization)

    • Serum bilirubin ≤ 1.5 x ULN
    • Serum transaminases ≤ 2.5 x ULN
  • Urine dipstick for proteinuria < 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours
  • Adequate postoperative GFR > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula are sufficient)

Exclusion Criteria:

  • Non-epithelial origin of the ovary, the fallopian tube or the peritoneum
  • Borderline tumours (tumours of low malignant potential) and FIGO stage Ia - IIa tumours
  • Planned intraperitoneal cytotoxic chemotherapy
  • Prior systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy or hormonal therapy)
  • Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for the fact that bevacizumab can be omitted from the first cycle of chemotherapy). It is strongly recommended that an interval of 7 days is left between the insertion of any central venous access devices (CVADs) and the onset of bevacizumab treatment.
  • Any planned surgery during the study treatment period plus 4 additional weeks to allow for bevacizumab clearance
  • Uncontrolled hypertension (sustained elevation of BP systolic > 150mmHg and/or diastolic > 100mmHg despite antihypertensive therapy)
  • Any previous radiotherapy to the abdomen or pelvis
  • Significant traumatic injury during 4 weeks preceding the potential first dose of bevacizumab
  • History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression.
  • History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy e.g. uncontrolled seizures
  • Previous Cerebro-Vascular Accident (CVA), Transient Ischaemic Attack (TIA) or Sub-Arachnoid Haemorrhage (SAH) within 6 months prior to randomization
  • Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the study duration and at least 6 months afterwards
  • Pregnant or lactating women
  • Treatment with other investigational agents, or participation in another clinical trial testing a drug within the past 4 weeks before start of therapy concomitantly with this trial
  • Malignancies other than ovarian cancer within 5 years prior to randomization, except for adequately treated

    • carcinoma in situ of the cervix
    • and/or basal cell skin cancer
    • and/or non-melanomatous skin cancer
    • carcinoma in situ of the breast
    • and/or early endometrial carcinoma as specified below. Patients may have received previous adjuvant chemotherapy for other malignancies e.g. breast or colorectal carcinoma if diagnosed over 5 years ago with no evidence of subsequent recurrence.
  • Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met

    • Disease stage FIGO stage ≤ IA (tumour invades less than one half of the myometrium)
  • Known hypersensitivity to bevacizumab and its excipients, Chinese hamster ovary cell products or other recombinant human or humanised antibodies
  • Non healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations
  • History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
  • Clinically significant cardiovascular disease, including

    • Myocardial infarction or unstable angina within 6 months of randomization
    • NYHA ≥ Grade 2 Congestive Heart Failure (CHF)
    • Poorly controlled cardiac arrhythmia despite medication (patients with rate-controlled atrial fibrillation are eligible)
    • Grade ≥ 3 peripheral vascular disease (i.e. symptomatic and interfering with activities of daily living requiring repair or revision)
  • Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day
  • Pre-existing sensory or motor neuropathy ≥ Grade 2
  • Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Control Arm

Research Arm

Arm Description

Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.

Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS)

Secondary Outcome Measures

Objective response rate (ORR)
Overall survival (OS)
Health related Quality of life (QoL)
Safety and tolerability, i.e. type, frequency, severity and duration of adverse reactions
Translational Research - Tumor Tissue Block
may be obtained at any time during therapy, preferably at cycle 1 or at a subsequent visit
Translational Research - Complementary and Alternative Treatment Questionnaires

Full Information

First Posted
October 25, 2011
Last Updated
July 19, 2022
Sponsor
AGO Study Group
Collaborators
ARCAGY/ GINECO GROUP, Nordic Society of Gynaecological Oncology - Clinical Trials Unit
search

1. Study Identification

Unique Protocol Identification Number
NCT01462890
Brief Title
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Acronym
BOOST
Official Title
A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
November 2011 (Actual)
Primary Completion Date
December 31, 2020 (Actual)
Study Completion Date
December 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AGO Study Group
Collaborators
ARCAGY/ GINECO GROUP, Nordic Society of Gynaecological Oncology - Clinical Trials Unit

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.
Detailed Description
Determination whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Keywords
Ovarian Carcinoma, Bevacizumab, Paclitaxel, Carboplatin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized Phase III study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
927 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Arm
Arm Type
Other
Arm Description
Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
Arm Title
Research Arm
Arm Type
Experimental
Arm Description
Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
Intervention Type
Biological
Intervention Name(s)
Bevacizumab
Intervention Description
15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
175 mg/m², iv on day 1 every 3 weeks for 6 cycles
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
AUC 5, iv on day 1 every 3 weeks for 6 cycles
Intervention Type
Other
Intervention Name(s)
specialized pathology review (Germany only)
Intervention Description
before randomization
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Time Frame
every 12 weeks until progression or up to 30 months, thereafter every 6 months
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Time Frame
every 12 weeks until progression or up to 30 months, thereafter every 6 months
Title
Overall survival (OS)
Time Frame
every 3 weeks, 31 months after start of treatment, thereafter every 6 months
Title
Health related Quality of life (QoL)
Time Frame
baseline, then every 12 weeks until progression, 31 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later)
Title
Safety and tolerability, i.e. type, frequency, severity and duration of adverse reactions
Time Frame
every 3 weeks, 31 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later)
Title
Translational Research - Tumor Tissue Block
Description
may be obtained at any time during therapy, preferably at cycle 1 or at a subsequent visit
Time Frame
Assessment at end of study planned
Title
Translational Research - Complementary and Alternative Treatment Questionnaires
Time Frame
baseline, 6 months and 12 months after start of treatment, if required at timepoint of treatment termination

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written informed consent obtained prior to initiation of any study specific procedures and treatment as confirmation of the patients awareness and willingness to comply with the study requirements Primary diagnosis is confirmed by specialized pathology review (Germany only) Females aged ≥ 18 years Histologically confirmed, newly diagnosed Epithelial ovarian carcinoma Fallopian tube carcinoma Primary peritoneal carcinoma AND FIGO stage IIb - IV (all grades and all histological types) Patients should have already undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction according to the GCIG Conference Consensus Statement. There must be no planned surgical debulking prior to disease progression. Patients with stage III and IV disease in whom initial surgical debulking was not appropriate or possible will still be eligible providing the patient has a histological diagnosis and debulking surgery prior to disease progression is not foreseen Patients must be able to commence cytotoxic chemotherapy within 8 weeks of cytoreductive surgery. The first dose of bevacizumab can be omitted in both arms if the investigator decides to start chemotherapy within 4 weeks of surgery. ECOG 0-2 Life expectancy > 3 months Adequate bone marrow function (within 14 days prior to randomization) ANC ≥ 1.5 x 10^9/L PLT ≥ 100 x 10^9/L Hb ≥ 9 g/dL (can be post-transfusion) Adequate coagulation parameters (within 14 days prior to randomization) Patients not receiving anticoagulant medication who have an INR ≤ 1.5 and an aPTT ≤ 1.5 x ULN The use of full-dose oral or par-enteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to institution medical standard) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization. Adequate liver function (within 14 days prior to randomization) Serum bilirubin ≤ 1.5 x ULN Serum transaminases ≤ 2.5 x ULN Urine dipstick for proteinuria < 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours Adequate postoperative GFR > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula are sufficient) Exclusion Criteria: Non-epithelial origin of the ovary, the fallopian tube or the peritoneum Borderline tumours (tumours of low malignant potential) and FIGO stage Ia - IIa tumours Planned intraperitoneal cytotoxic chemotherapy Prior systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy or hormonal therapy) Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for the fact that bevacizumab can be omitted from the first cycle of chemotherapy). It is strongly recommended that an interval of 7 days is left between the insertion of any central venous access devices (CVADs) and the onset of bevacizumab treatment. Any planned surgery during the study treatment period plus 4 additional weeks to allow for bevacizumab clearance Uncontrolled hypertension (sustained elevation of BP systolic > 150mmHg and/or diastolic > 100mmHg despite antihypertensive therapy) Any previous radiotherapy to the abdomen or pelvis Significant traumatic injury during 4 weeks preceding the potential first dose of bevacizumab History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy e.g. uncontrolled seizures Previous Cerebro-Vascular Accident (CVA), Transient Ischaemic Attack (TIA) or Sub-Arachnoid Haemorrhage (SAH) within 6 months prior to randomization Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the study duration and at least 6 months afterwards Pregnant or lactating women Treatment with other investigational agents, or participation in another clinical trial testing a drug within the past 4 weeks before start of therapy concomitantly with this trial Malignancies other than ovarian cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer and/or non-melanomatous skin cancer carcinoma in situ of the breast and/or early endometrial carcinoma as specified below. Patients may have received previous adjuvant chemotherapy for other malignancies e.g. breast or colorectal carcinoma if diagnosed over 5 years ago with no evidence of subsequent recurrence. Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met Disease stage FIGO stage ≤ IA (tumour invades less than one half of the myometrium) Known hypersensitivity to bevacizumab and its excipients, Chinese hamster ovary cell products or other recombinant human or humanised antibodies Non healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization Clinically significant cardiovascular disease, including Myocardial infarction or unstable angina within 6 months of randomization NYHA ≥ Grade 2 Congestive Heart Failure (CHF) Poorly controlled cardiac arrhythmia despite medication (patients with rate-controlled atrial fibrillation are eligible) Grade ≥ 3 peripheral vascular disease (i.e. symptomatic and interfering with activities of daily living requiring repair or revision) Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day Pre-existing sensory or motor neuropathy ≥ Grade 2 Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacobus Pfisterer, MD PhD
Organizational Affiliation
AGO Study Group
Official's Role
Study Chair
Facility Information:
City
Aalborg
Country
Denmark
City
Copenhagen
Country
Denmark
City
Herlev
Country
Denmark
City
Kuopio
Country
Finland
City
Oulu
Country
Finland
City
Tampere
Country
Finland
City
Turku
Country
Finland
City
Angers
Country
France
City
Besancon
Country
France
City
Blois
Country
France
City
Bordeaux
Country
France
City
Caen
Country
France
City
Cahors
Country
France
City
Clamart
Country
France
City
Clermont-Ferrand
Country
France
City
Creteil
Country
France
City
Dax
Country
France
City
Draguignan
Country
France
City
Grenoble
Country
France
City
Limoges
Country
France
City
Lyon
Country
France
City
Mougins
Country
France
City
Nancy
Country
France
City
Nantes
Country
France
City
Nice
Country
France
City
Nimes
Country
France
City
Orleans
Country
France
City
Paris
Country
France
City
Pau
Country
France
City
Plérin
Country
France
City
Poitiers
Country
France
City
Quimper
Country
France
City
Reims
Country
France
City
Rouen
Country
France
City
Saint-Herblain
Country
France
City
Strasbourg
Country
France
City
Toulouse
Country
France
City
Vandoeuvre-Les-Nancy
Country
France
City
Vannes
Country
France
City
Villejuif
Country
France
City
Aachen
Country
Germany
City
Arnsberg
Country
Germany
City
Aschaffenburg
Country
Germany
City
Augsburg
Country
Germany
City
Bad Homburg vor der Höhe
Country
Germany
City
Berlin
Country
Germany
City
Bochum
Country
Germany
City
Bonn
Country
Germany
City
Bottrop
Country
Germany
City
Brandenburg
Country
Germany
City
Bremen
Country
Germany
City
Chemnitz
Country
Germany
City
Coburg
Country
Germany
City
Deggendorf
Country
Germany
City
Dessau
Country
Germany
City
Dresden
Country
Germany
City
Düsseldorf
Country
Germany
City
Ebersberg
Country
Germany
City
Eggenfelden
Country
Germany
City
Erlangen
Country
Germany
City
Essen
Country
Germany
City
Esslingen
Country
Germany
City
Flensburg
Country
Germany
City
Frankfurt/M.
Country
Germany
City
Freiburg
Country
Germany
City
Fürstenfeldbruck
Country
Germany
City
Fürth
Country
Germany
City
Georgsmarienhütte
Country
Germany
City
Gera
Country
Germany
City
Greifswald
Country
Germany
City
Göttingen
Country
Germany
City
Gütersloh
Country
Germany
City
Halle (Saale)
Country
Germany
City
Hamburg
Country
Germany
City
Hanau am Main
Country
Germany
City
Hannover
Country
Germany
City
Heidelberg
Country
Germany
City
Henstedt-Ulzburg
Country
Germany
City
Hildesheim
Country
Germany
City
Jena
Country
Germany
City
Kaiserslautern
Country
Germany
City
Karlsruhe
Country
Germany
City
Kassel
Country
Germany
City
Kiel
Country
Germany
City
Krefeld
Country
Germany
City
Köln
Country
Germany
City
Lich
Country
Germany
City
Limburg
Country
Germany
City
Lübeck
Country
Germany
City
Lüneburg
Country
Germany
City
Magdeburg
Country
Germany
City
Mainz
Country
Germany
City
Mannheim
Country
Germany
City
Marburg
Country
Germany
City
Minden
Country
Germany
City
München
Country
Germany
City
Neumarkt
Country
Germany
City
Neuss
Country
Germany
City
Nordhausen
Country
Germany
City
Offenbach
Country
Germany
City
Offenburg
Country
Germany
City
Oldenburg
Country
Germany
City
Osnabrück
Country
Germany
City
Ravensburg
Country
Germany
City
Regensburg
Country
Germany
City
Reutlingen
Country
Germany
City
Rosenheim
Country
Germany
City
Rostock
Country
Germany
City
Rottweil
Country
Germany
City
Saalfeld
Country
Germany
City
Salzgitter
Country
Germany
City
Schweinfurt
Country
Germany
City
Schwäbisch Hall
Country
Germany
City
Sigmaringen
Country
Germany
City
Solingen
Country
Germany
City
Stralsund
Country
Germany
City
Stuttgart
Country
Germany
City
Torgau
Country
Germany
City
Trier
Country
Germany
City
Tübingen
Country
Germany
City
Ulm
Country
Germany
City
Viersen
Country
Germany
City
Wiesbaden
Country
Germany
City
Witten
Country
Germany
City
Wolfsburg
Country
Germany
City
Worms
Country
Germany
City
Bergen
Country
Norway
City
Oslo
Country
Norway
City
Trondheim
Country
Norway
City
Falun
Country
Sweden
City
Uppsala
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36332161
Citation
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Luck HJ, Emons G, Meier W, Gropp-Meier M, Schroder W, de Gregorio N, Hilpert F, Harter P. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. 2023 Feb 1;41(4):893-902. doi: 10.1200/JCO.22.01010. Epub 2022 Nov 4.
Results Reference
derived

Learn more about this trial

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

We'll reach out to this number within 24 hrs